Suppr超能文献

用于靶向放射性核素治疗的(177)镥的生产:可用选项。

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

作者信息

Dash Ashutosh, Pillai Maroor Raghavan Ambikalmajan, Knapp Furn F

机构信息

Isotope Production and Applications Division, Bhabha Atomic Research Centre (BARC), Trombay, Mumbai 400 085 India.

Molecular Group of Companies, Kochi, 780001 Kerala India.

出版信息

Nucl Med Mol Imaging. 2015 Jun;49(2):85-107. doi: 10.1007/s13139-014-0315-z. Epub 2015 Feb 17.

Abstract

BACKGROUND

This review provides a comprehensive summary of the production of (177)Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of (177)Lu having the required quality for preparation of a variety of (177)Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of (177)Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success.

METHODS

While both "direct" and "indirect" reactor production routes offer the possibility for sustainable (177)Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies.

RESULTS

This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future.

CONCLUSION

A broad understanding and discussion of the issues associated with (177)Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of (177)Lu-labeled radiopharmaceuticals, but also help future developments.

摘要

背景

本综述全面总结了¹⁷⁷Lu的生产情况,以满足未来预期的研究和临床需求。多种选择的存在是¹⁷⁷Lu常规生产可持续增长的基石,要生产出具有制备各种¹⁷⁷Lu标记放射性药物所需质量的足够活度水平的¹⁷⁷Lu。¹⁷⁷Lu用于靶向放射性核素治疗(TRT)的巨大前景表明,应从整体上考虑所有决定其成功的关键因素。

方法

虽然“直接”和“间接”反应堆生产路线都为¹⁷⁷Lu的可持续供应提供了可能性,但要充分发挥这些生产策略的潜力,还必须考虑若干问题和挑战。

结果

本文对最新进展、现状、关键挑战以及近期的可能性进行了简要综述。

结论

对与¹⁷⁷Lu生产和加工方法相关的问题进行广泛的理解和讨论,不仅能确保¹⁷⁷Lu标记放射性药物的供应和使用实现持续增长及未来扩展,还将有助于未来的发展。

相似文献

1
Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.
Nucl Med Mol Imaging. 2015 Jun;49(2):85-107. doi: 10.1007/s13139-014-0315-z. Epub 2015 Feb 17.
2
Preparation of Patient Doses of [Lu]Lu-DOTATATE and [Lu]Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) Lu.
Nucl Med Mol Imaging. 2022 Dec;56(6):313-322. doi: 10.1007/s13139-022-00778-y. Epub 2022 Oct 7.
3
Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP.
Australas Phys Eng Sci Med. 2018 Mar;41(1):69-79. doi: 10.1007/s13246-017-0611-x. Epub 2017 Dec 19.
5
6
Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.
J Appl Clin Med Phys. 2016 Nov 8;17(6):128-139. doi: 10.1120/jacmp.v17i6.6375.
9
A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Nucl Med Biol. 2010 Jul;37(5):655-63. doi: 10.1016/j.nucmedbio.2010.02.007. Epub 2010 May 6.
10
Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
Nucl Med Biol. 2011 Apr;38(3):417-25. doi: 10.1016/j.nucmedbio.2010.09.013. Epub 2010 Dec 3.

引用本文的文献

1
PSMA-Directed Theranostics in Prostate Cancer.
Biomedicines. 2025 Jul 28;13(8):1837. doi: 10.3390/biomedicines13081837.
2
Compact accelerator-based production of carrier-free Lu from 18 MeV on [Yb] .
EJNMMI Radiopharm Chem. 2025 Aug 25;10(1):56. doi: 10.1186/s41181-025-00358-3.
6
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.
Biomimetics (Basel). 2025 Jun 11;10(6):394. doi: 10.3390/biomimetics10060394.
7
Towards a dry separation method of radioscandium from bulk amounts of titanium.
J Radioanal Nucl Chem. 2025;334(5):3359-3366. doi: 10.1007/s10967-025-10092-4. Epub 2025 Apr 19.
8
Radiation Synovectomy: An Enticing Treatment Option for Inflammatory Joint Pain.
Pain Res Manag. 2025 May 13;2025:8887391. doi: 10.1155/prm/8887391. eCollection 2025.
10
Pr Visible to Ultraviolet Upconversion for Antimicrobial Applications.
Nanomaterials (Basel). 2025 Apr 6;15(7):562. doi: 10.3390/nano15070562.

本文引用的文献

3
Targeted radionuclide therapy--an overview.
Curr Radiopharm. 2013 Sep;6(3):152-80. doi: 10.2174/18744710113066660023.
4
Tumour targeting with radiometals for diagnosis and therapy.
Chem Commun (Camb). 2013 May 25;49(42):4720-39. doi: 10.1039/c3cc41554f.
6
Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide.
Bioorg Med Chem Lett. 2013 Apr 15;23(8):2319-23. doi: 10.1016/j.bmcl.2013.02.069. Epub 2013 Feb 24.
7
Radionuclide synovectomy in haemophilic joints.
Nucl Med Commun. 2013 Apr;34(4):291-7. doi: 10.1097/MNM.0b013e32835ed50c.
9
Radiometals for combined imaging and therapy.
Chem Rev. 2013 Feb 13;113(2):858-83. doi: 10.1021/cr3003104. Epub 2012 Nov 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验